Intravenous Immunoglobulin (IVIG) is commonly used for the treatment of a wide range of autoimmune diseases. The available data also suggest that IVIG has a steroid-sparing effect: either enhancing the steroid sensitivity or reducing the steroid dose. These reports indicate that IVIG can be considered as a therapeutic choice in steroid-resistant autoimmune and inflammatory diseases such as dermatomyositis, asthma, and polymyositis. We aimed to identify the underlying molecular mechanisms by which IVIG therapy can restore steroid sensitivity and can act as a "steroid-sparing" agent.

We addressed the steroid-sparing effect of IVIG by analyzing the affinity of glucocorticoid receptor (GCR) using lymphoblastoid cell line CEM-C1. CEM-C1 is resistant to steroids despite its expression of functional GCR and hence represents an apposite model to study the steroid-sparing effect of IVIG.

Octagam® (Octapharma, Lingolsheim, France) was used as a source of IVIG in all the experiments. GCR-binding affinity was determined by [3H]-dexamethasone ([3H]-Dex) radioligand binding assays and Scatchard analysis. The cells were incubated with increasing concentrations of [3H]-dexamethasone (Amersham Corp., Arlington Heights, IL, USA; range 0.1–50 nM) in the presence or absence of 500-fold excess of nonlabeled [3H]-dexamethasone (Sigma Chemical Co., St. Louis, MO, USA) for 60 min. After incubation, the cells were rinsed, lysed, and counted in a β-spectrometer.

Pretreatment of CEM-C1 cells with IVIG followed by dexamethasone (10 µM) led to an increase in apoptosis as compared to dexamethasone alone. We thus assessed whether this increase in sensitivity of CEM-C1 to dexamethasone was due to the changes in GCR-binding affinity during IVIG treatment. The baseline GCR dissociation constant (Kd) of CEM-C1 was at 7.36 nM level. Interestingly, after 2 h of IVIG treatment of cells, the mean Kd had significantly fallen to 3.12 nM (Figure 1), suggesting an enhancement of affinity for GCR by IVIG.

Long-term steroid use is associated with many debilitating adverse effects and hence several alternative steroid-sparing agents including cyclosporine and mepolizumab have been used. IVIG therapy has been reported to have steroid-sparing effects with relatively few adverse effects. The mechanisms involved in steroid-sparing effects of IVIG are not fully understood but may involve immunomodulation. Using a steroid-resistant CEM-C1 cell model, our results suggest that one of the steroid-sparing effects of IVIG is mediated through the improved GCR-binding affinity.

**Figure 1.** Scatchard analysis of [3H]-dexamethasone radioligand binding data of CEM-1 cells. Black triangles represent cells treated with 0.24 nM IVIG for 2 h.